Tissue platinum concentrations linked to response in NSCLC

August 14, 2012
Tissue platinum concentrations linked to response in NSCLC
For patients with non-small-cell lung cancer who undergo neoadjuvant platinum-based chemotherapy, tissue platinum concentrations correlate positively with improved outcome, according to a study published online Aug. 13 in the Journal of Clinical Oncology.

(HealthDay) -- For patients with non-small-cell lung cancer (NSCLC) who undergo neoadjuvant platinum-based chemotherapy, tissue platinum concentrations correlate positively with improved outcome, according to a study published online Aug. 13 in the Journal of Clinical Oncology.

Eric S. Kim, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues used flameless atomic absorption spectrophotometry to measure total platinum concentrations in 44 archived fresh-frozen specimens from patients who underwent surgical resection after neoadjuvant platinum-based chemotherapy. The effect of tissue platinum concentration on response and survival was examined.

The researchers observed a significant association between tissue platinum concentration and percent reduction in . This association was also seen with cisplatin, carboplatin, and all histology subgroups. Variables such as the number of cycles and time lapse from last chemotherapy had no significant impact on platinum concentration. Time to recurrence, progression-free survival, and overall survival were significantly longer in patients with higher platinum concentration, after adjustment for the number of cycles.

"Our data strongly support reduced drug accumulation as a significant mechanism of platinum resistance," the authors write. "Enhanced understanding of the molecular mechanism of platinum accumulation by will be necessary to identify surrogate biomarkers for platinum accumulation that could be developed prospectively for individualizing therapy."

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Drug cocktail boosts ovarian cancer survival time

June 2, 2012

A drug cocktail that combines chemotherapy with Avastin was shown to double the amount of time patients lived without progression of ovarian cancer, according to research released Saturday.

Recommended for you

Study reveals new insight into DNA repair

August 3, 2015

DNA double-strand breaks (DSBs) are the worst possible form of genetic malfunction that can cause cancer and resistance to therapy. New information published this week reveals more about why this occurs and how these breaks ...

Strange circular DNA may offer new way to detect cancers

July 30, 2015

Strange rings of DNA that exist outside chromosomes are distinct to the cell types that mistakenly produced them, researchers have discovered. The finding raises the tantalizing possibility that the rings could be used as ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.